Healthcare provider profile · identity verified

Dawn Barker, D.O.

Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, MO · NPI 1982080255

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Dawn Barker, D.O. received $91.54 in general payments during 2025 across 5 reported records.

Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 35.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$91.54

5 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Salix Pharmaceuticals, a division of Bausch Health US, LLC	Unresolved — no canonical attribution shown	$32.75	35.8%	2	2025
Abbott Laboratories	Unresolved — no canonical attribution shown	$23.88	26.1%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$18.28	20.0%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$16.63	18.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$91.54	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
XIFAXAN Normalized: xifaxan	Drug	Salix Pharmaceuticals, a division of Bausch Health US, LLC	$32.75	2	2025
Source payment records 2025-02-11 · Salix Pharmaceuticals, a division of Bausch Health US, LLC · $17.54 · Open Payments source 2025-04-28 · Salix Pharmaceuticals, a division of Bausch Health US, LLC · $15.21 · Open Payments source
FREESTYLE LIBRE Normalized: freestyle libre	Device	Abbott Laboratories	$23.88	1	2025
Source payment records 2025-04-02 · Abbott Laboratories · $23.88 · Open Payments source
BREZTRI Normalized: breztri	Drug	AstraZeneca Pharmaceuticals LP	$18.28	1	2025
Source payment records 2025-05-21 · AstraZeneca Pharmaceuticals LP · $18.28 · Open Payments source
SHINGRIX Normalized: shingrix	Biological	GlaxoSmithKline, LLC.	$16.63	1	2025
Source payment records 2025-04-30 · GlaxoSmithKline, LLC. · $16.63 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	30	11
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	575	234
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	435	82
Lisinopril	Lisinopril	366	163
Gabapentin	Gabapentin	351	101
Levothyroxine Sodium	Levothyroxine Sodium	333	131
Alprazolam	Alprazolam	308	49
Amlodipine Besylate	Amlodipine Besylate	283	106
Albuterol Sulfate Hfa	Albuterol Sulfate	273	73
Metformin Hcl	Metformin Hcl	258	90
Omeprazole	Omeprazole	247	94
Pantoprazole Sodium	Pantoprazole Sodium	245	77
Tramadol Hcl	Tramadol Hcl	223	48
Fluticasone Propionate	Fluticasone Propionate	220	80
Furosemide	Furosemide	202	77
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	196	31
Losartan Potassium	Losartan Potassium	167	74
Eliquis	Apixaban	151	40
Metoprolol Succinate	Metoprolol Succinate	146	66
Montelukast Sodium	Montelukast Sodium	138	40
Metoprolol Tartrate	Metoprolol Tartrate	137	55
Tizanidine Hcl	Tizanidine Hcl	135	38
Potassium Chloride	Potassium Chloride	133	55
Carvedilol	Carvedilol	132	49
Trazodone Hcl	Trazodone Hcl	130	44
Rosuvastatin Calcium	Rosuvastatin Calcium	128	51
Sertraline Hcl	Sertraline Hcl	122	40
Oxycodone Hcl	Oxycodone Hcl	119	21
Diazepam	Diazepam	114	25
Meloxicam	Meloxicam	112	43
Tamsulosin Hcl	Tamsulosin Hcl	111	42
Allopurinol	Allopurinol	110	39
Duloxetine Hcl	Duloxetine Hcl	110	36
Clopidogrel	Clopidogrel Bisulfate	103	33
Simvastatin	Simvastatin	100	43
Clonazepam	Clonazepam	98	21
Lorazepam	Lorazepam	94	24
Pravastatin Sodium	Pravastatin Sodium	92	25
Paroxetine Hcl	Paroxetine Hcl	85	16
Morphine Sulfate Er	Morphine Sulfate	82	12
Hydrochlorothiazide	Hydrochlorothiazide	81	38
Famotidine	Famotidine	76	34
Glimepiride	Glimepiride	76	28
Citalopram Hbr	Citalopram Hydrobromide	75	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	30
Pregabalin	Pregabalin	64	19
Ropinirole Hcl	Ropinirole Hcl	63	20
Zolpidem Tartrate	Zolpidem Tartrate	63	15
Buspirone Hcl	Buspirone Hcl	62	20
Clonidine Hcl	Clonidine Hcl	60	18
Xarelto	Rivaroxaban	58	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	56	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	56	17
Metformin Hcl Er	Metformin Hcl	55	21
Jardiance	Empagliflozin	53	19
Diclofenac Sodium	Diclofenac Sodium	50	17
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	50	18
Fluoxetine Hcl	Fluoxetine Hcl	50	20
Venlafaxine Hcl Er	Venlafaxine Hcl	48	14
Hydralazine Hcl	Hydralazine Hcl	47	13
Warfarin Sodium	Warfarin Sodium	46	13
Escitalopram Oxalate	Escitalopram Oxalate	45	15
Fentanyl	Fentanyl	44	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	44	15
Finasteride	Finasteride	43	18
Lovastatin	Lovastatin	43	17
Mirtazapine	Mirtazapine	43	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	42	suppressed
Spironolactone	Spironolactone	42	17
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	41	suppressed
Levetiracetam	Levetiracetam	40	suppressed
Topiramate	Topiramate	40	12
Januvia	Sitagliptin Phosphate	39	12
Breo Ellipta	Fluticasone/Vilanterol	38	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	36	suppressed
Baclofen	Baclofen	35	suppressed
Donepezil Hcl	Donepezil Hcl	34	suppressed
Atenolol	Atenolol	33	13
Ibuprofen	Ibuprofen	32	12
Nystatin	Nystatin	32	20
Pioglitazone Hcl	Pioglitazone Hcl	32	12
Alendronate Sodium	Alendronate Sodium	31	16
Symbicort	Budesonide/Formoterol Fumarate	30	11
Bupropion Hcl Sr	Bupropion Hcl	29	suppressed
Cimetidine	Cimetidine	29	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	29	suppressed
Ozempic	Semaglutide	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	29	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	29	12
Ventolin Hfa	Albuterol Sulfate	29	suppressed
Nifedipine Er	Nifedipine	28	suppressed
Glipizide	Glipizide	27	suppressed
Movantik	Naloxegol Oxalate	27	suppressed
Propranolol Hcl	Propranolol Hcl	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	16
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	27	suppressed
Nitroglycerin	Nitroglycerin	26	21
Novolog Flexpen	Insulin Aspart	26	suppressed
Spiriva Handihaler	Tiotropium Bromide	26	suppressed
Bupropion Xl	Bupropion Hcl	25	suppressed
Fluconazole	Fluconazole	25	suppressed
Naproxen	Naproxen	25	suppressed
Promethazine Hcl	Promethazine Hcl	24	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	13
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Ondansetron Odt	Ondansetron	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Lamotrigine	Lamotrigine	21	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Prednisone	Prednisone	21	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Bumetanide	Bumetanide	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	16
Benazepril Hcl	Benazepril Hcl	19	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Mounjaro	Tirzepatide	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Colchicine	Colchicine	18	suppressed
Digoxin	Digoxin	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Lidocaine	Lidocaine	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Celecoxib	Celecoxib	17	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Mupirocin	Mupirocin	16	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	16	suppressed
Terbinafine Hcl	Terbinafine Hcl	16	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	15	suppressed
Levemir Flexpen	Insulin Detemir	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Testosterone Cypionate	Testosterone Cypionate	15	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Verapamil Sr	Verapamil Hcl	15	suppressed
Victoza 3-Pak	Liraglutide	15	suppressed
Dexlansoprazole Dr	Dexlansoprazole	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	12
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	14	suppressed
Rexulti	Brexpiprazole	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Atrovent Hfa	Ipratropium Bromide	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Brilinta	Ticagrelor	13	suppressed
Guanfacine Hcl	Guanfacine Hcl	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Temazepam	Temazepam	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Valsartan	Valsartan	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Flecainide Acetate	Flecainide Acetate	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	12	suppressed
Ramipril	Ramipril	12	suppressed
Estradiol	Estradiol	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Linzess	Linaclotide	11	suppressed
Savella	Milnacipran Hcl	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$91.54 · 5 records	Salix Pharmaceuticals, a division of Bausch Health US, LLC	BREZTRI, FREESTYLE LIBRE, SHINGRIX, XIFAXAN	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error